SOLV Solventum
FY2025 10-K
Solventum (SOLV) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
- • Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
Management Discussion & Analysis
- • Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
- • Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
Risk Factors
- • 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
- • $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
Financial SummaryXBRL
Revenue
$8.3B
Net Income
$1.6B
Gross Margin
53.5%
Operating Margin
26.2%
Net Margin
18.7%
ROE
30.8%
Total Assets
$14.3B
EPS (Diluted)
$8.88
Operating Cash Flow
$369M
Source: XBRL data from Solventum FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Solventum Annual Reports
Get deeper insights on Solventum
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.